Scholarlink

Background <p>Myocardial hypertrophy (MH) is one of the key features of pathological cardiac hypertrophy (CH). MicroRNAs (miRNAs) possess significant regulatory potential in MH. This study aims to investigate the potential function and molecular mechanisms of miR-654-3p in MH.</p> Methods <p>An in vitro MH model was established by treating AC16 cells with 200 nM Ang II. Changes in miR-654-3p and markers of MH and myocardial fibrosis (MF) were assessed using RT-qPCR. Changes in oxidative stress (OS) markers were evaluated using ELISA. The binding capacity of miR-654-3p to HDAC2 was validated via dual luciferase assays and RIP experiments. The functional relationship was verified through rescue experiments.</p> Results <p>Following Ang II stimulation, miR-654-3p was reduced in AC16 cells, whilst HDAC2 levels increased. Concurrently, mRNA levels of MH markers rose, MDA levels increased, and SOD activity decreased. Overexpression of miR-654-3p improved these parameters, whereas inhibition of miR-654-3p exacerbated the damage. Rescue experiments demonstrated that the addition of oe-HDAC2 could reverse the anti-hypertrophic, anti-fibrotic, and anti-OS effects mediated by the miR-654-3p mimic.</p> Conclusions <p>Overexpression of miR-654-3p alleviates MH and OS by directly targeting and downregulating HDAC2. The miR-654-3p/HDAC2 axis may represent a potential regulatory mechanism for MH.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Overexpression of miR-654-3p may inhibit myocardial hypertrophy via HDAC2

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月29日

查看全文
  • Yu Wang,
  • Weiling Huang,
  • Xianwei Tian

摘要

Background

Myocardial hypertrophy (MH) is one of the key features of pathological cardiac hypertrophy (CH). MicroRNAs (miRNAs) possess significant regulatory potential in MH. This study aims to investigate the potential function and molecular mechanisms of miR-654-3p in MH.

Methods

An in vitro MH model was established by treating AC16 cells with 200 nM Ang II. Changes in miR-654-3p and markers of MH and myocardial fibrosis (MF) were assessed using RT-qPCR. Changes in oxidative stress (OS) markers were evaluated using ELISA. The binding capacity of miR-654-3p to HDAC2 was validated via dual luciferase assays and RIP experiments. The functional relationship was verified through rescue experiments.

Results

Following Ang II stimulation, miR-654-3p was reduced in AC16 cells, whilst HDAC2 levels increased. Concurrently, mRNA levels of MH markers rose, MDA levels increased, and SOD activity decreased. Overexpression of miR-654-3p improved these parameters, whereas inhibition of miR-654-3p exacerbated the damage. Rescue experiments demonstrated that the addition of oe-HDAC2 could reverse the anti-hypertrophic, anti-fibrotic, and anti-OS effects mediated by the miR-654-3p mimic.

Conclusions

Overexpression of miR-654-3p alleviates MH and OS by directly targeting and downregulating HDAC2. The miR-654-3p/HDAC2 axis may represent a potential regulatory mechanism for MH.